Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM | Eli Lilly and Company

Generating your feed, please be patient ...

Latest news

Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM | Eli Lilly and Company | Zootzle

Trending today

Latest news